Goldman Sachs refreshes its high-conviction U.S. buy list, adds Vertex and removes Interactive Brokers
Goldman Sachs updated its U.S. high-conviction buy list for September, keeping the roster at 23 stocks while adding Vertex Pharmaceuticals and removing Interactive Brokers Group. In its Sept. 1 monthly report, the bank said the entire gain in U.S. equities during August was concentrated in the first two trading days of the month. After that, markets drifted into a summer trading range, with risk assets lacking a clear direction even after Nvidia delivered strong earnings. Goldman said the 10-year Treasury yield rose 9 basis points from the start of the month, Brent crude was little changed, and gold, silver and Bitcoin gained 9%, 22% and 24%, respectively. Against what it described as a catalyst vacuum, the firm argued that better opportunities may lie in companies undergoing material change that could set a new direction for the fourth quarter. Goldman highlighted Vertex as the most notable addition, with analyst Salveen Richter pointing to five potential multi-billion-dollar commercial opportunities across cystic fibrosis, pain, kidney disease, hematology and endocrinology. The report also reviewed strong August performers such as Estée Lauder, DoorDash and TPG, while maintaining buy views on laggards including Viking Holdings and Applied Materials despite recent stock pressure.








